Measurement of tumor antioxidant capacity and prediction of chemotherapy resistance in preclinical models of ovarian cancer by positron emission tomography.

CONCLUSIONS: This study demonstrates the ability of [18F]FSPG to detect upregulated antioxidant pathways present in drug-resistant cancer. [18F]FSPG may therefore enable the identification of HGSOC patients that are refractory to standard-of-care, allowing the transferral of drug-resistant patients to alternative therapies, thereby improving outcomes in this disease.
PMID: 30651275 [PubMed - as supplied by publisher]

Source: Clinical Cancer Research - January 16, 2019 Category: Cancer & Oncology Authors: Greenwood HE, McCormick PN, Gendron T, Glaser M, Pereira R, Maddocks ODK, Sander K, Zhang T, Koglin N, Lythgoe MF, Årstad E, Hochhauser D, Witney TH Tags: Clin Cancer Res Source Type: research